Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ).
JOINN Laboratories (China) reported robust unaudited results for the first quarter of 2026, with revenue rising 10.02% year on year to RMB316.1 million and net profit attributable to shareholders surging 479.67% to RMB238.4 million. Profitability improved sharply as net profit after excluding non-recurring items jumped 747.11%, basic and diluted earnings per share increased to RMB0.32, and operating cash flow nearly doubled, signaling stronger operational efficiency and enhanced returns for shareholders, with weighted average return on net assets climbing to 2.82%.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$16.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
More about JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. is a Beijing-based contract research organization operating in the biomedical and pharmaceutical testing industry. The group provides preclinical research and related laboratory services under PRC Accounting Standards, serving drug developers and healthcare clients in domestic and international markets.
Average Trading Volume: 3,976,556
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.5B
Learn more about 6127 stock on TipRanks’ Stock Analysis page.